Clearmind’s $1.38M Direct Offering, Israeli Patent Filing and Trial Expansion Ignite 26% Stock Surge
By ATTN Desk · Editorial oversight: Sean Han
Introduction
CLEARMIND MEDICINE INC (Nasdaq: CMND) is a Vancouver-based biotechnology company founded in 2021 that develops psychedelic-inspired therapies for alcohol use disorder, binge eating, and depression. Trading on the NAS exchange under ticker CMND, the stock closed at USD 0.3500 on November 18, 2025—an increase of 26.40% on a volume of 4,211,424 shares.
| Metric | Value |
|---|---|
| Price | 0.3500 USD |
| Change (24 hours) | +26.40% |
| Volume | 4,211,424 |
| 52-Week Range | 0.2400 – 2.1800 USD |
| Market Capitalization | 1.918 million USD |
Corporate Structure
Clearmind Medicine employs between 11 and 50 staff and has scientific and clinical teams led by Dr. Adi Zuloff-Shani, a biomedical R&D executive with over 20 years of experience in regulated environments. The company’s operations are headquartered in Vancouver, British Columbia, and it maintains a proprietary IP portfolio focused on self-administered, non-hallucinogenic neuroplastogens.
Psychedelic therapy by Alexander Grey
Recent Developments and News
- November 17, 2025 (Form 6-K): Clearmind filed for an Israeli patent covering a non-hallucinogenic neuroplastogen treatment for depression.
- November 17, 2025 (Form 6-K): The company announced a registered direct offering of 3,991,768 common shares at USD 0.25 each, plus pre-funded warrants for 1,518,000 shares at USD 0.2499. Gross proceeds are expected to total approximately USD 1.377 million, which will be used for clinical and pre-clinical testing, working capital, and potential acquisitions.
- November 18, 2025 (Schedule 13G/A): An amendment indicated that Richard Abbe beneficially owns 603,470 shares (9.94%) and Iroquois Capital Management, LLC holds 310,990 shares (5.38%). These holdings include shares issuable upon exercise of warrants.
- Clinical Trial Update: Hadassah Medical Center in Jerusalem granted final approval to expand the Phase 1/2a trial of CMND-100 (an MEAI-based oral candidate) for alcohol use disorder.
Financial and Strategic Analysis
As of the trailing twelve months ending September 30, 2025, Clearmind reported a net loss of USD 4.05 million and a diluted EPS of -0.75. Cash on hand totaled USD 3.50 million, with a debt-to-equity ratio of 2.67%. Levered free cash flow was -4.13 million. Return on equity was -178.64%, and return on assets was -59.68%.
The direct offering aims to raise USD 1.377 million to support ongoing R&D and operational expenses, while the Israeli patent filing reflects the firm’s focus on intellectual property. The significant shareholdings by Richard Abbe and Iroquois Capital Management may influence corporate governance and indicate institutional involvement.
Market Position and Industry Context
The global substance abuse treatment market is estimated at USD 193 billion, and the market for alcohol-related disorders is estimated at USD 249 billion. Among 1,302 registered psychedelic clinical trials, only 21 (1.6%) target alcohol-related conditions. Clearmind’s MEAI platform positions it within a sector with low competitive density, focusing on offering differentiated, self-administered therapies for binge behaviour and mental health disorders.
tl;dr
• November 17, 2025: Filed for an Israeli patent on a non-hallucinogenic neuroplastogen for depression.
• November 17–18, 2025: Announced and expects to close a USD 1.377 million direct offering for shares and warrants.
• November 18, 2025: Schedule 13G/A shows Richard Abbe (9.94%) and Iroquois Capital (5.38%) as major shareholders.
• Hadassah Medical Center approved the expansion of the Phase 1/2a trial for CMND-100 in alcohol use disorder. These developments support Clearmind’s efforts in intellectual property growth, funding for clinical programs, and an evolving shareholder base.